Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.02 EUR | 208.38% |
| 2022 | -0.02 EUR | -189.5% |
| 2021 | 0.02 EUR | -99.06% |
| 2020 | 2.13 EUR | 66662.5% |
| 2019 | -0.00 EUR | -60.0% |
| 2018 | -0.00 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.01 EUR | 150.76% |
| 2024 Q2 | 0.11 EUR | 1000.0% |
| 2024 Q3 | -0.00 EUR | -103.73% |
| 2023 Q4 | -0.02 EUR | -201.55% |
| 2023 Q2 | 0.01 EUR | 0.0% |
| 2023 Q3 | 0.02 EUR | 100.0% |
| 2023 Q1 | 0.01 EUR | 120.29% |
| 2023 FY | - EUR | 208.38% |
| 2022 Q4 | -0.05 EUR | -1065.85% |
| 2022 FY | - EUR | -189.5% |
| 2022 Q3 | -0.00 EUR | -115.95% |
| 2022 Q2 | 0.03 EUR | 84.89% |
| 2022 Q1 | 0.01 EUR | 167.31% |
| 2021 Q2 | -0.01 EUR | -103.13% |
| 2021 FY | - EUR | -99.06% |
| 2021 Q4 | 0.01 EUR | 842.86% |
| 2021 Q3 | -0.00 EUR | 93.0% |
| 2021 Q1 | 0.32 EUR | -85.19% |
| 2020 Q1 | 0.00 EUR | 0.0% |
| 2020 Q3 | 0.01 EUR | 476.0% |
| 2020 Q2 | -0.00 EUR | -266.67% |
| 2020 Q4 | 2.16 EUR | 22878.72% |
| 2020 FY | - EUR | 66662.5% |
| 2019 FY | - EUR | -60.0% |
| 2018 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AroCell AB (publ) | -0.26 SEK | 107.692% |
| Devyser Diagnostics AB (publ) | -3.31 SEK | 100.604% |
| Immunovia AB (publ) | -7.38 SEK | 100.271% |
| Prostatype Genomics AB (publ) | -0.24 SEK | 108.333% |
| SenzaGen AB | -0.91 SEK | 102.198% |
| Spermosens AB | -0.15 SEK | 113.333% |